BACKGROUND: Little information exists regarding pediatric contrast-enhanced US. OBJECTIVE: To assess the safety and feasibility of contrast-enhanced US of pediatric @entity530 . MATERIALS AND METHODS: This prospective study included eight @entity1 and five @entity1 (mean age, 10.8 years) with @entity530 . Cohorts of three subjects underwent US with perflutren contrast agent at escalating dose levels. Neurological and funduscopic examination, electrocardiography and continuous pulse oximetry were performed before and after contrast administration. Three radiologists independently scored six imaging parameters on pre- and postcontrast sonography. Inter-reviewer agreement was measured by the Kappa statistic. RESULTS: No neurological, retinal, electrocardiographical or pulse oximetry changes were attributable to the contrast agent. Two subjects reported minor, transient symptoms. Postcontrast US parameter scores improved slightly in 8 of 12 subjects. Postcontrast ultrasound inter-reviewer agreement improved slightly for detection of @entity5 margins (precontrast = 0.20, postcontrast = 0.26), @entity5 invasion (precontrast = -0.01, postcontrast = 0.10) and @entity3018 (precontrast = 0.35, postcontrast = 0.44). CONCLUSIONS: Although our sample size is small, perflutren contrast agents appear to be safe and well tolerated in @entity1 . Contrast-enhanced sonography of pediatric @entity530 is feasible, but larger studies are needed to define their safety and efficacy in @entity1 .

Contrast-enhanced sonography of XXXX : preliminary safety and feasibility data.

@entity530 :: ('MESH:D010386', 'Disease') :: ['abdominal and pelvic tumors', 'abdominal or pelvic tumors'] @entity1 :: ('9606', 'Species') :: ['children', 'girls', 'boys'] @entity3018 :: ('MESH:D009377', 'Disease') :: ['adenopathy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'local tumor']
@entity5 :: (MESH:D009369,Disease) :: ['malignant pediatric abdominal and pelvic solid tumors']
